InvestSMART

Ceretas Limited (ASX: CTS) - Share Price

Current share price for CTS : $1.045 0.035 (3.24%)+

Ceretas Limited (CTS) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is engaged in research and development of a novel therapeutic ultrasound technology licensed from UniQuest for the purpose of commercialising a portable, image-guided therapeutic ultrasound platform designed for the treatment of neurodegenerative disease, particularly Alzheimer's disease.

CTS General Information +

ASX Code CTS
Website http://www.ceretas.com.au
Industry/Sector Health Care Equipment
Market Cap ($M) 50
CTS Share Price $1.045
Day High $1.105
Day Low $1.035
Last Close $1.080
CTS Share Price Movement $0.04 ( 3.24% )
Prices as at 16:40, 7 Sep 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Ceretas Limited (CTS) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Ceretas Limited (CTS) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Ceretas Limited (CTS) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Ceretas Limited (CTS)
ORDINARY FULLY PAID
 Health Care $51 Ethics Committee Approval Secured for Additional Trial Sites 31 Aug 2026 8:58AM $0.900 $1.045 risen by 16.11%
Ceretas Limited (CTS)
ORDINARY FULLY PAID
 Health Care $51 Appendix 4G 31 Aug 2026 8:30AM $0.900 $1.045 risen by 16.11%
Ceretas Limited (CTS)
ORDINARY FULLY PAID
 Health Care $51 Corporate Governance Statement 31 Aug 2026 8:27AM $0.900 $1.045 risen by 16.11%
Ceretas Limited (CTS)
ORDINARY FULLY PAID
 Health Care $51 Appendix 4E & Annual Report 30 June 2026 31 Aug 2026 8:24AM $0.900 $1.045 risen by 16.11%
Ceretas Limited (CTS)
ORDINARY FULLY PAID
 Health Care $51 Change of Address 14 Aug 2026 4:22PM $0.700 $1.045 risen by 49.29%
Ceretas Limited (CTS)
ORDINARY FULLY PAID
 Health Care $51 Investor Presentation 13 Aug 2026 10:39AM $0.660 $1.045 risen by 58.33%

CTS Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$0.18 -$0.30 0.00% 0.00 0.00 0.00% 0.0%

CTS Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2025 A 2025 A 2025 A
Cochlear Limited (COH) $9,219M -0.3136 0.2540 0.0785 34.3201 27.3686 25.3767 2.45% 2.54% 2.77%
Ceretas Limited (CTS) $51M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Fisher & Paykel Healthcare Corporation Limited (FPH) $21,312M 0.1388 0.1617 0.1748 54.7860 47.1622 40.1440 1.20% 1.29% 1.46%
ResMed Inc. (RMD) $18,976M 9.5922 0.0984 0.0886 20.8363 18.9691 17.4251 1.12% 1.21% 1.31%

CTS Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 0.00 0.00
Market 0.35 13.60 1.17 0.81
Sector 0.63 20.10 2.04 2.52

CTS Directors

Name Position Start Date
Ms Rachel de las Heras Chief Executive Officer, Managing Director 11 Mar 2025
Dr Anthony J Keating Executive Director 20 Dec 2024
Mr John Keep Non-Executive Chairman, Non-Executive Director 22 Nov 2024
Mr Stuart Crozier Non-Executive Director 20 Feb 2026
Mr Samuel Alan Wetzler Non-Executive Director 21 Oct 2024

Ceretas Limited (CTS) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value

See all changes in directors' interest & trades for Ceretas Limited (CTS) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

CTS Management

Name Position
Nicola (Nicki) Maxine Farley Company Secretary

CTS Calendar of Events

Date Event
30 August 2027 Report (Annual)
30 August 2027 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.